Ourotech slide deck
•Download as PPTX, PDF•
0 likes•69 views
Ourotech is developing a hydrogel that mimics tumor microenvironments to test cancer drug resistance outside the body. Their solution involves obtaining tumor samples, growing them in a 96-well plate using the proprietary hydrogel, testing drug and combination treatments, and calculating human dosages. This allows personalized cancer treatment by determining the most effective drugs without trial and error. They have proof of concept data showing their hydrogel can better predict drug resistance compared to other methods. With $1.5M funding, they plan to finish preclinical trials, seek FDA clearance, generate revenue from pharmaceutical clients, and further develop the technology.
Report
Share
Report
Share
Recommended
Ourotech Investor Deck Feb 2017
Ourotech is developing a hydrogel that mimics tumor microenvironments to test cancer drug responses in vitro. Their solution involves obtaining patient tumor samples, growing them in a 96-well plate using a proprietary hydrogel, testing drug and combination treatments, calculating human dosages, and treating the patient. They have shown their hydrogel can better predict drug resistance compared to competitors. With $1.5M funding, they plan to complete preclinical trials, generate revenue from pharmaceutical clients, and develop new prototypes.
MDC Connects: Designing a Biomarker Strategy
A biomarker strategy aims to answer key clinical questions to support drug development through identifying and testing biomarkers. Developing a robust biomarker strategy can mitigate risks and inform clinical study design by generating testable hypotheses to bridge pre-clinical and clinical research. Effective biomarker strategies consider assay suitability, study design, and sample availability to reliably detect biomarkers and provide statistically meaningful results. Emerging technologies allow deeper interrogation of drugs and disease through multiplexed readouts to enhance biomarker discovery and clinical development.
Webinar: Turning Molecules into Medicines
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
MDC Connects: Evaluation of clinical preclinical pharmacodynamic endpoints us...
MDC Connects: Evaluation of clinical preclinical pharmacodynamic endpoints us...Medicines Discovery Catapult
Imaging can be used to evaluate pharmacodynamic endpoints in both preclinical and clinical studies. Preclinically, imaging such as PET can provide quantitative data on endpoints like tumor metabolism without invasive procedures. This can help reduce animal studies. Clinically, imaging biomarkers for conditions like osteoporosis, heart disease, and cancer provide anatomical and functional data on targets, proliferation, and hypoxia. Case studies demonstrate how imaging endpoints like tumor size and blood flow changes can support decision making in drug development from early research through approval. Imaging is positioned to continue advancing drug discovery by identifying new pharmacodynamic biomarkers.MDC Connect: Imaging technologies to understand the pharmacokinetics and biod...
MDC Connect: Imaging technologies to understand the pharmacokinetics and biod...Medicines Discovery Catapult
This document discusses how in vivo imaging can be used to understand the distribution of candidate compounds in the body. It provides examples of how various imaging modalities such as positron emission tomography (PET), near infrared imaging, and mass spectrometry imaging can be used to track the accumulation of compounds in organs, penetration into tissues, and ability to cross barriers like the blood brain barrier. The document emphasizes how imaging can accelerate drug development by providing visualization of biological processes and quantifying pharmacokinetics, target engagement, and toxicity.Rheumatoid Arthritis Treatment Landscape
With significant unmet needs for RA patients, it's more important than ever to overcome your Rheumatoid Arthritis development pain points with an experienced and trusted partner.
MDC Connects: Understanding PK/PD using pre-clinical models: Lessons for effi...
MDC Connects: Understanding PK/PD using pre-clinical models: Lessons for effi...Medicines Discovery Catapult
1) Understanding the relationship between pharmacokinetics (PK) and pharmacodynamics (PD) through preclinical PKPD studies is important for determining effective drug doses and schedules.
2) Successful PKPD study design requires integrating knowledge across disciplines and testing a range of doses, time points, and biological parameters to understand target modulation and optimize efficacy while minimizing toxicity.
3) Case studies demonstrate how PKPD analysis of oncology and respiratory disease models identified optimal dosing schedules, with the oncology study changing from a daily high dose to thrice weekly lower doses to improve efficacy without toxicity.MDC Connects: How to Get your Molecule into Humans
This document discusses strategies for efficiently developing the non-clinical package needed to get a molecule into human trials. It outlines top reasons for delays like insufficient API, formulation issues, and unexpected toxicity. It recommends enhancing efficiency by selecting a CRO early, combining study endpoints, using biomarkers to inform clinical decisions, and microsampling to reduce animal numbers. Looking ahead, the future may see increased use of minipigs and humanized models with reduced primate use. Developing a defined strategy, partnership with an experienced CRO, and planning for unexpected events are crucial to improving efficiency.
Recommended
Ourotech Investor Deck Feb 2017
Ourotech is developing a hydrogel that mimics tumor microenvironments to test cancer drug responses in vitro. Their solution involves obtaining patient tumor samples, growing them in a 96-well plate using a proprietary hydrogel, testing drug and combination treatments, calculating human dosages, and treating the patient. They have shown their hydrogel can better predict drug resistance compared to competitors. With $1.5M funding, they plan to complete preclinical trials, generate revenue from pharmaceutical clients, and develop new prototypes.
MDC Connects: Designing a Biomarker Strategy
A biomarker strategy aims to answer key clinical questions to support drug development through identifying and testing biomarkers. Developing a robust biomarker strategy can mitigate risks and inform clinical study design by generating testable hypotheses to bridge pre-clinical and clinical research. Effective biomarker strategies consider assay suitability, study design, and sample availability to reliably detect biomarkers and provide statistically meaningful results. Emerging technologies allow deeper interrogation of drugs and disease through multiplexed readouts to enhance biomarker discovery and clinical development.
Webinar: Turning Molecules into Medicines
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
MDC Connects: Evaluation of clinical preclinical pharmacodynamic endpoints us...
MDC Connects: Evaluation of clinical preclinical pharmacodynamic endpoints us...Medicines Discovery Catapult
Imaging can be used to evaluate pharmacodynamic endpoints in both preclinical and clinical studies. Preclinically, imaging such as PET can provide quantitative data on endpoints like tumor metabolism without invasive procedures. This can help reduce animal studies. Clinically, imaging biomarkers for conditions like osteoporosis, heart disease, and cancer provide anatomical and functional data on targets, proliferation, and hypoxia. Case studies demonstrate how imaging endpoints like tumor size and blood flow changes can support decision making in drug development from early research through approval. Imaging is positioned to continue advancing drug discovery by identifying new pharmacodynamic biomarkers.MDC Connect: Imaging technologies to understand the pharmacokinetics and biod...
MDC Connect: Imaging technologies to understand the pharmacokinetics and biod...Medicines Discovery Catapult
This document discusses how in vivo imaging can be used to understand the distribution of candidate compounds in the body. It provides examples of how various imaging modalities such as positron emission tomography (PET), near infrared imaging, and mass spectrometry imaging can be used to track the accumulation of compounds in organs, penetration into tissues, and ability to cross barriers like the blood brain barrier. The document emphasizes how imaging can accelerate drug development by providing visualization of biological processes and quantifying pharmacokinetics, target engagement, and toxicity.Rheumatoid Arthritis Treatment Landscape
With significant unmet needs for RA patients, it's more important than ever to overcome your Rheumatoid Arthritis development pain points with an experienced and trusted partner.
MDC Connects: Understanding PK/PD using pre-clinical models: Lessons for effi...
MDC Connects: Understanding PK/PD using pre-clinical models: Lessons for effi...Medicines Discovery Catapult
1) Understanding the relationship between pharmacokinetics (PK) and pharmacodynamics (PD) through preclinical PKPD studies is important for determining effective drug doses and schedules.
2) Successful PKPD study design requires integrating knowledge across disciplines and testing a range of doses, time points, and biological parameters to understand target modulation and optimize efficacy while minimizing toxicity.
3) Case studies demonstrate how PKPD analysis of oncology and respiratory disease models identified optimal dosing schedules, with the oncology study changing from a daily high dose to thrice weekly lower doses to improve efficacy without toxicity.MDC Connects: How to Get your Molecule into Humans
This document discusses strategies for efficiently developing the non-clinical package needed to get a molecule into human trials. It outlines top reasons for delays like insufficient API, formulation issues, and unexpected toxicity. It recommends enhancing efficiency by selecting a CRO early, combining study endpoints, using biomarkers to inform clinical decisions, and microsampling to reduce animal numbers. Looking ahead, the future may see increased use of minipigs and humanized models with reduced primate use. Developing a defined strategy, partnership with an experienced CRO, and planning for unexpected events are crucial to improving efficiency.
Gene Express Jaima Presentation September 04, 2008 Chiba
This document discusses the challenges and opportunities of molecular diagnostics and personalized medicine. It defines personalized medicine as using a patient's genetic information to tailor their medical care. The two key components are pharmaceuticals and molecular diagnostics. Existing business models for pharma focus on high volume and high margins, while molecular diagnostics focuses on high volume and low margins. Standardization of molecular diagnostic assays is challenging under the current system. Reimbursement is also a major challenge for widespread adoption of molecular diagnostics. The document suggests government reforms are needed to address reimbursement issues and help realize the potential of personalized medicine.
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacy
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacyMedicines Discovery Catapult
This document discusses using preclinical models to demonstrate proof of concept efficacy for new cancer therapies. It outlines services available from Alderley Oncology including efficacy, pharmacokinetic and biomarker studies using mouse xenograft and syngeneic models. Case studies are presented on an FGFR inhibitor and PI3K inhibitor, showing how the right preclinical models helped validate mechanisms of action and identify patient populations most likely to respond. Successful preclinical studies for the FGFR inhibitor led to ongoing clinical trials in lung cancer. Exploring the PI3K inhibitor in syngeneic models revealed a novel immune-mediated mechanism of action.3D printed drug delivery systems
3D printed drug delivery systems have the potential to address limitations of traditional oral dosage forms for pediatric and geriatric patients. 3D printing allows for more complex product designs and personalized medicine by producing customized dosage forms on demand. Some benefits include reduced manufacturing steps, integrated healthcare networks with mini-dispenser units, and novel designs to overcome hurdles of traditional medicine. However, further work is needed to reduce costs, enable larger scale production, and speed up processing times, as well as obtain regulatory approval through existing pathways.
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...Medicines Discovery Catapult
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life SciencesInnovation in patient care
While companies no more possesses deep and extensive product pipeline, this is the perfect time to innovate! Innovate not only in terms of product (although that is the core), but also
MDC Connects: Strategies for target and pathway engagement in cellular assays
MDC Connects: Strategies for target and pathway engagement in cellular assaysMedicines Discovery Catapult
This document discusses strategies for demonstrating target engagement in cellular assays. It notes that lack of efficacy is a major cause of drug failure and that showing target engagement can improve success. The document outlines various approaches for assessing if a compound reaches its target and engages with it in a cellular environment, including biochemical assays, cellular thermal shift assays, bioluminescence resonance energy transfer, and examining downstream markers. The goal is to validate that leads are engaging their intended target and modulating the disease pathway.MDC Connect: Optimising ADME and PK properties: Common mistakes made and how ...
MDC Connect: Optimising ADME and PK properties: Common mistakes made and how ...Medicines Discovery Catapult
The document discusses optimizing ADME and PK properties in drug development. It addresses common mistakes such as believing that intrinsic clearance cannot be optimized or that increasing plasma protein binding will always benefit PK. It emphasizes that intrinsic clearance, uptake clearance, and renal clearance all contribute to in vivo clearance. Good quality experimental data is important for accurate prediction of human PK. Formulation strategies can improve bioavailability when absorption is limited, but not if clearance is the dominant elimination pathway. The effects of plasma protein binding on free drug exposure are also explained.MDC Connects: Making Safety Part of Drug Design
This document discusses the importance of incorporating safety considerations into drug design from an early stage. It notes that safety issues related to the primary drug target remain a major reason for drug project failure and delay. Considering the target's normal physiological role allows researchers to anticipate and plan for potential toxicities. Early studies, such as in silico modeling, in vitro screening assays, and in vivo validations in animal models, can help identify potential safety hazards to hopefully design them out of drug candidates. Understanding toxicity risks in the context of the intended patient population can help assess the risk-benefit of a given drug target or compound series. Incorporating safety assessments from the beginning of the drug design process can lead to better informed decisions and improved chances of
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...ErisTollkuciPharmDBC
This document summarizes the key points of a chemotherapy dose rounding policy implemented at a medical institution. It describes how published literature has shown dose rounding can save tens of thousands to millions annually. The policy allows rounding doses within 10% of the prescribed amount. It also requires an interdisciplinary consensus for institutional guidelines. A review of three medications found dose rounding reduced vials and saved over $237,000 in an 8 month period.MDC Connects: Biomarker identification - Assessing Immune Function
This document discusses biomarkers for assessing immune function throughout the drug development process. It describes how various techniques can be used to identify, validate, and qualify biomarkers. These include flow cytometry to analyze cell populations and activation markers, Luminex to measure cytokine levels, and gene expression profiling using NanoString. Whole blood stimulation assays are discussed as a way to assess target engagement and immune responses ex vivo. The importance of assay validation and understanding sources of variation are also covered. Biomarkers can provide insights into mechanisms of action, safety, and efficacy to support clinical development.
KIF1A.ORG Path to Treatment
KIF1A.ORG is a parent-led non-profit organization established in 2017 to fund research for KIF1A Associated Neurological Disorder (KAND), a rare neurodegenerative disorder with no available treatments. The organization has made progress in supporting researchers at Columbia University who launched the world's first pre-clinical research program for KAND in 2017. This document outlines KIF1A.ORG's strategy to translate current pre-clinical research into clinical trials and treatments for KAND patients by 2020, including defining research objectives and required resources.
MDC Connects: Go native… Characterising therapeutic effect in primary cellula...
MDC Connects: Go native… Characterising therapeutic effect in primary cellula...Medicines Discovery Catapult
This document discusses the advantages of using primary cellular models in drug development. Primary cells better mimic native biology and target expression compared to cell lines. Several case studies are presented where primary cellular models helped validate drug targets and identify potential safety issues prior to clinical trials. The document emphasizes characterizing fit-for-purpose models to generate relevant data at each stage of development from discovery to clinical translation. Thorough assay development and validation are important to support clinical applications.MDC Connects: Target discovery at AstraZeneca
Target discovery is important to reduce drug attrition rates. AstraZeneca uses various target discovery platforms including CRISPR screening to identify novel targets. An example project used CRISPR libraries in prostate cancer cell lines to identify new regulators of androgen receptor stability, which could provide novel treatment targets for castrate resistant prostate cancer.
MDC Connects Series 2021 | A Guide to Complex Medicines: Determining Efficacy...
MDC Connects Series 2021 | A Guide to Complex Medicines: Determining Efficacy...Medicines Discovery Catapult
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at how you can determine efficacy in vivo.
Jenny Worthington (Axis Bio)The Impact of High Cost Oncology Drugs
Oncology drugs are extremely expensive, with some costing over $100,000 per treatment course. This high cost is due to drug development costs, market exclusivity from patents, and companies prioritizing profits. However, these drug prices strain healthcare budgets and reduce access. To address this, governments are implementing value-based drug pricing and health technology assessments. In the future, personalized treatments and collaborations may help control costs while continuing to advance cancer care.
AkrodouY-Week7 Project Part 2a
This document discusses the integration of pharmacogenomics into clinical trials. It defines pharmacogenomics as investigating drug responses based on genes, with the goal of predicting side effects and making personalized drug therapy. The causes of using pharmacogenomics in clinical trials include increasing drug failures, costs, and complex diseases. Pharmacogenomics can contribute to innovation in drug discovery and development by allowing targeted drugs tailored to individuals. However, challenges include a lack of standard methods and high costs. Overall, pharmacogenomics holds promise for the future by enabling precision medicine through rigorous research.
UNC Eshelman School of Pharmacy Highlights
The document describes the UNC Eshelman School of Pharmacy as a recognized leader in pharmacy education, practice, and research. It provides details on its academic programs, research centers focused on drug discovery and development, and partnerships within UNC and with outside organizations. The School has over 100 faculty conducting research across therapeutic areas from discovery through clinical practice, and seeks to enhance its research enterprise through partnerships with industry.
PRECLINICAL DRUG STUDIES AT CBSET
Over the past decade CBSET has partnered with more than 400+ MedTech and BioTech companies, including start-ups and industry-leading corporations, enabling them to initiate clinical studies and gain subsequent US and OUS market approvals for their novel therapeutic, imaging and diagnostic technologies.
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...Medicines Discovery Catapult
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the advantages of good formulation.
Claire Patterson, Seda Pharmaceutical Development ServicesOurotech pitch deck
Ourotech develops personalized cancer treatments using a proprietary hydrogel scaffold to test drug resistance. The company grows tumor samples in a 96-well plate using the hydrogel to test drugs and combinations, calculate dosages, and treat patients. Preliminary results show the hydrogel model matches human drug resistance levels. Ourotech seeks $1.5 million in funding to expand preclinical trials with hospitals and pharmaceutical partners to optimize products and services testing drug resistance for personalized cancer treatment.
Dendreon.Final
Dendreon is a biotechnology company focused on developing immunotherapies for cancer treatment. Their first product, Provenge, received FDA approval in 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Provenge involves extracting a patient's antigen-presenting cells and combining them with a recombinant prostate antigen to stimulate an immune response against prostate cancer cells. Dendreon is working to expand Provenge's market and develop new immunotherapy treatments targeting antigens like HER2/neu, CA-9, and CEA expressed on other cancer types. They face challenges in scaling up manufacturing and achieving reimbursement to fully commercialize Provenge in the US and expand into Europe.
More Related Content
What's hot
Gene Express Jaima Presentation September 04, 2008 Chiba
This document discusses the challenges and opportunities of molecular diagnostics and personalized medicine. It defines personalized medicine as using a patient's genetic information to tailor their medical care. The two key components are pharmaceuticals and molecular diagnostics. Existing business models for pharma focus on high volume and high margins, while molecular diagnostics focuses on high volume and low margins. Standardization of molecular diagnostic assays is challenging under the current system. Reimbursement is also a major challenge for widespread adoption of molecular diagnostics. The document suggests government reforms are needed to address reimbursement issues and help realize the potential of personalized medicine.
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacy
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacyMedicines Discovery Catapult
This document discusses using preclinical models to demonstrate proof of concept efficacy for new cancer therapies. It outlines services available from Alderley Oncology including efficacy, pharmacokinetic and biomarker studies using mouse xenograft and syngeneic models. Case studies are presented on an FGFR inhibitor and PI3K inhibitor, showing how the right preclinical models helped validate mechanisms of action and identify patient populations most likely to respond. Successful preclinical studies for the FGFR inhibitor led to ongoing clinical trials in lung cancer. Exploring the PI3K inhibitor in syngeneic models revealed a novel immune-mediated mechanism of action.3D printed drug delivery systems
3D printed drug delivery systems have the potential to address limitations of traditional oral dosage forms for pediatric and geriatric patients. 3D printing allows for more complex product designs and personalized medicine by producing customized dosage forms on demand. Some benefits include reduced manufacturing steps, integrated healthcare networks with mini-dispenser units, and novel designs to overcome hurdles of traditional medicine. However, further work is needed to reduce costs, enable larger scale production, and speed up processing times, as well as obtain regulatory approval through existing pathways.
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...Medicines Discovery Catapult
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life SciencesInnovation in patient care
While companies no more possesses deep and extensive product pipeline, this is the perfect time to innovate! Innovate not only in terms of product (although that is the core), but also
MDC Connects: Strategies for target and pathway engagement in cellular assays
MDC Connects: Strategies for target and pathway engagement in cellular assaysMedicines Discovery Catapult
This document discusses strategies for demonstrating target engagement in cellular assays. It notes that lack of efficacy is a major cause of drug failure and that showing target engagement can improve success. The document outlines various approaches for assessing if a compound reaches its target and engages with it in a cellular environment, including biochemical assays, cellular thermal shift assays, bioluminescence resonance energy transfer, and examining downstream markers. The goal is to validate that leads are engaging their intended target and modulating the disease pathway.MDC Connect: Optimising ADME and PK properties: Common mistakes made and how ...
MDC Connect: Optimising ADME and PK properties: Common mistakes made and how ...Medicines Discovery Catapult
The document discusses optimizing ADME and PK properties in drug development. It addresses common mistakes such as believing that intrinsic clearance cannot be optimized or that increasing plasma protein binding will always benefit PK. It emphasizes that intrinsic clearance, uptake clearance, and renal clearance all contribute to in vivo clearance. Good quality experimental data is important for accurate prediction of human PK. Formulation strategies can improve bioavailability when absorption is limited, but not if clearance is the dominant elimination pathway. The effects of plasma protein binding on free drug exposure are also explained.MDC Connects: Making Safety Part of Drug Design
This document discusses the importance of incorporating safety considerations into drug design from an early stage. It notes that safety issues related to the primary drug target remain a major reason for drug project failure and delay. Considering the target's normal physiological role allows researchers to anticipate and plan for potential toxicities. Early studies, such as in silico modeling, in vitro screening assays, and in vivo validations in animal models, can help identify potential safety hazards to hopefully design them out of drug candidates. Understanding toxicity risks in the context of the intended patient population can help assess the risk-benefit of a given drug target or compound series. Incorporating safety assessments from the beginning of the drug design process can lead to better informed decisions and improved chances of
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...ErisTollkuciPharmDBC
This document summarizes the key points of a chemotherapy dose rounding policy implemented at a medical institution. It describes how published literature has shown dose rounding can save tens of thousands to millions annually. The policy allows rounding doses within 10% of the prescribed amount. It also requires an interdisciplinary consensus for institutional guidelines. A review of three medications found dose rounding reduced vials and saved over $237,000 in an 8 month period.MDC Connects: Biomarker identification - Assessing Immune Function
This document discusses biomarkers for assessing immune function throughout the drug development process. It describes how various techniques can be used to identify, validate, and qualify biomarkers. These include flow cytometry to analyze cell populations and activation markers, Luminex to measure cytokine levels, and gene expression profiling using NanoString. Whole blood stimulation assays are discussed as a way to assess target engagement and immune responses ex vivo. The importance of assay validation and understanding sources of variation are also covered. Biomarkers can provide insights into mechanisms of action, safety, and efficacy to support clinical development.
KIF1A.ORG Path to Treatment
KIF1A.ORG is a parent-led non-profit organization established in 2017 to fund research for KIF1A Associated Neurological Disorder (KAND), a rare neurodegenerative disorder with no available treatments. The organization has made progress in supporting researchers at Columbia University who launched the world's first pre-clinical research program for KAND in 2017. This document outlines KIF1A.ORG's strategy to translate current pre-clinical research into clinical trials and treatments for KAND patients by 2020, including defining research objectives and required resources.
MDC Connects: Go native… Characterising therapeutic effect in primary cellula...
MDC Connects: Go native… Characterising therapeutic effect in primary cellula...Medicines Discovery Catapult
This document discusses the advantages of using primary cellular models in drug development. Primary cells better mimic native biology and target expression compared to cell lines. Several case studies are presented where primary cellular models helped validate drug targets and identify potential safety issues prior to clinical trials. The document emphasizes characterizing fit-for-purpose models to generate relevant data at each stage of development from discovery to clinical translation. Thorough assay development and validation are important to support clinical applications.MDC Connects: Target discovery at AstraZeneca
Target discovery is important to reduce drug attrition rates. AstraZeneca uses various target discovery platforms including CRISPR screening to identify novel targets. An example project used CRISPR libraries in prostate cancer cell lines to identify new regulators of androgen receptor stability, which could provide novel treatment targets for castrate resistant prostate cancer.
MDC Connects Series 2021 | A Guide to Complex Medicines: Determining Efficacy...
MDC Connects Series 2021 | A Guide to Complex Medicines: Determining Efficacy...Medicines Discovery Catapult
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at how you can determine efficacy in vivo.
Jenny Worthington (Axis Bio)The Impact of High Cost Oncology Drugs
Oncology drugs are extremely expensive, with some costing over $100,000 per treatment course. This high cost is due to drug development costs, market exclusivity from patents, and companies prioritizing profits. However, these drug prices strain healthcare budgets and reduce access. To address this, governments are implementing value-based drug pricing and health technology assessments. In the future, personalized treatments and collaborations may help control costs while continuing to advance cancer care.
AkrodouY-Week7 Project Part 2a
This document discusses the integration of pharmacogenomics into clinical trials. It defines pharmacogenomics as investigating drug responses based on genes, with the goal of predicting side effects and making personalized drug therapy. The causes of using pharmacogenomics in clinical trials include increasing drug failures, costs, and complex diseases. Pharmacogenomics can contribute to innovation in drug discovery and development by allowing targeted drugs tailored to individuals. However, challenges include a lack of standard methods and high costs. Overall, pharmacogenomics holds promise for the future by enabling precision medicine through rigorous research.
UNC Eshelman School of Pharmacy Highlights
The document describes the UNC Eshelman School of Pharmacy as a recognized leader in pharmacy education, practice, and research. It provides details on its academic programs, research centers focused on drug discovery and development, and partnerships within UNC and with outside organizations. The School has over 100 faculty conducting research across therapeutic areas from discovery through clinical practice, and seeks to enhance its research enterprise through partnerships with industry.
PRECLINICAL DRUG STUDIES AT CBSET
Over the past decade CBSET has partnered with more than 400+ MedTech and BioTech companies, including start-ups and industry-leading corporations, enabling them to initiate clinical studies and gain subsequent US and OUS market approvals for their novel therapeutic, imaging and diagnostic technologies.
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...Medicines Discovery Catapult
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the advantages of good formulation.
Claire Patterson, Seda Pharmaceutical Development ServicesWhat's hot (20)
Gene Express Jaima Presentation September 04, 2008 Chiba
Gene Express Jaima Presentation September 04, 2008 Chiba
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacy
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacy
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...
MDC Connects: Strategies for target and pathway engagement in cellular assays
MDC Connects: Strategies for target and pathway engagement in cellular assays
MDC Connect: Optimising ADME and PK properties: Common mistakes made and how ...
MDC Connect: Optimising ADME and PK properties: Common mistakes made and how ...
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
MDC Connects: Biomarker identification - Assessing Immune Function
MDC Connects: Biomarker identification - Assessing Immune Function
MDC Connects: Go native… Characterising therapeutic effect in primary cellula...
MDC Connects: Go native… Characterising therapeutic effect in primary cellula...
MDC Connects Series 2021 | A Guide to Complex Medicines: Determining Efficacy...
MDC Connects Series 2021 | A Guide to Complex Medicines: Determining Efficacy...
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...
Similar to Ourotech slide deck
Ourotech pitch deck
Ourotech develops personalized cancer treatments using a proprietary hydrogel scaffold to test drug resistance. The company grows tumor samples in a 96-well plate using the hydrogel to test drugs and combinations, calculate dosages, and treat patients. Preliminary results show the hydrogel model matches human drug resistance levels. Ourotech seeks $1.5 million in funding to expand preclinical trials with hospitals and pharmaceutical partners to optimize products and services testing drug resistance for personalized cancer treatment.
Dendreon.Final
Dendreon is a biotechnology company focused on developing immunotherapies for cancer treatment. Their first product, Provenge, received FDA approval in 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Provenge involves extracting a patient's antigen-presenting cells and combining them with a recombinant prostate antigen to stimulate an immune response against prostate cancer cells. Dendreon is working to expand Provenge's market and develop new immunotherapy treatments targeting antigens like HER2/neu, CA-9, and CEA expressed on other cancer types. They face challenges in scaling up manufacturing and achieving reimbursement to fully commercialize Provenge in the US and expand into Europe.
GENE Investor Deck May 2023
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Pros and Cons of Research Outcomes Week 12 discussion power point
The document summarizes research outcomes on four topics:
1) A study found that prescribing broad-spectrum antibiotics to children did not achieve better outcomes than narrow-spectrum antibiotics and increased harmful effects.
2) A study concluded that daily blood sugar monitoring provided little value for type 2 diabetes patients compared to foregoing monitoring.
3) Two studies provided new evidence on side effect rates of different prostate cancer treatment options like surgery and radiation to help patients decide.
4) In conclusion, the document emphasizes the importance of keeping evidence-based practice in patient care and focusing on research outcomes to inform clinical decisions.
GENE Presentation
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Get the right cancer drug, at right Time
Mitra Biotech is a Boston and Bengaluru-based startup that is developing personalized cancer therapies. It focuses on testing drugs on recreated tumor microenvironments in the lab before human trials. This approach has higher success rates and lower toxicity than conventional trials. Mitra Biotech has raised over $27 million to develop these personalized therapies and diagnostics. Major challenges include high costs, ensuring data quality, and coordinating information between different treatment centers.
April 2017 Corporate Presentation
This investor presentation summarizes Oncolytics Biotech's REOLYSIN viral therapy program. It highlights statistically significant increases in overall survival seen in phase 2 trials in metastatic breast cancer and pancreatic cancer. The clinical development plan focuses on three pathways: chemotherapy combinations as the first registration pathway, immunotherapy combinations with agents like pembrolizumab, and targeted therapy combinations using agents like pomalidomide. Safety data from over 1,100 patients shows a good toxicity profile. Manufacturing is established at commercial scale and the company has a strong patent portfolio. The leadership team has extensive experience in oncology drug development.
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...European School of Oncology
1) The non-profit health organization Clalit Health Services in Israel will fund the Oncotype DX test for breast cancer patients to determine who would benefit from chemotherapy and who could avoid it.
2) Oncotype DX testing changed the treatment recommendation in 40% of cases, avoiding chemotherapy in 84% deemed at low risk of recurrence by the test.
3) The added cost of Oncotype DX testing was partially offset by savings from avoiding chemotherapy and resulted in a cost-effectiveness ratio of $10,770 per quality-adjusted life year gained.Genetic technologies Investor Presentation
The document provides an overview of Genetic Technologies Company (GTG), including:
- GTG is developing genetic risk assessment products to prevent disease morbidity and mortality.
- GTG has 20 years experience commercializing genomics products and research partnerships with universities and companies.
- GTG's flagship product BREVAGenplus predicts a woman's risk of developing breast cancer using a cheek swab and has been clinically validated in multiple populations.
Prima BioMed Investor Presentation March 2011
Developing the world’s first Ovarian Cancer Therapy Vaccine RBC Capital Healthcare Conference – March 2011
Certis Innovation Brochure
Certis Oncology provides precision oncology solutions through patient-derived tumor xenograft (PDOX) mouse models. Their technique implants small samples of patients' tumors into mice to test potential drug therapies. This identifies effective and ineffective treatments faster than standard methods. It also enables tumor banking for future testing. Certis works with oncologists, patients, and pharmaceutical companies to advance precision cancer care and drug development.
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
The document discusses Canada's orphan drug regulatory framework and opportunities to improve access to rare disease drugs across Canada. It advocates for a life-cycle approach and managed access schemes where drugs are approved with evidence collection requirements. Traditional health technology assessment limits orphan drug access by rejecting drugs that are not cost-effective based on small clinical trials. The document recommends performance-based managed access programs with national guidelines and risk-sharing between provinces, patients, and companies to improve access while collecting long-term evidence on benefits, harms, and costs.Clinical trials ppt. Dr. Zubair Ali
Clinical trials have evolved since the 18th century to become a rigorous process for testing new medical treatments. There are typically four phases of clinical trials. Phase I trials test safety in small groups. Phase II explores efficacy. Phase III tests effectiveness against standard treatments in large groups. Phase IV monitors long-term safety post-approval. Clinical trials must include women, children, and pregnant women if a drug will be used to treat those populations, to determine safety under controlled conditions.
Call on Congress 2014 John Marshall, Treatment
Treatment: It’s no longer “one size fits all”
John Marshall, MD, Georgetown University Medical Center
Vital Signs Edition #3
The document summarizes recent news and events in oncology, including:
1) Daiichi Sankyo's acquisition of Plexxikon for its promising drug PLX4032 that targets the BRAF mutation in melanoma.
2) Positive results from Roche's phase 2 trial of its hedgehog pathway inhibitor vismodegib for advanced basal cell carcinoma.
3) How next-generation sequencing is enabling more personalized cancer treatment by matching drugs to patients based on their tumor's molecular profile.
Gene Presentation October 2019
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
Newsletter IMODI #3 - March 2017
ZOOM ON: Breast cancer: what’s new?
• NEWS: Big pharma acquire a new collection of PDX
• IMODI around the world: Meet the experts!
• FOCUS on: The Leon Berard Clinical Center
• ADVERT: A new web catalogue for IMODI products
Md flux dx4 week 10
The document discusses an innovative nutritional diagnostic tool called MDflux that allows dietitians and doctors to precisely assess a patient's nutritional state and needs. It found that standard hospital care often results in overfeeding or undernourishment of patients. MDflux provides actionable data to personalize nutrition and support healing. Key learnings included that dietitians are the main stakeholders, there is potential in neonatal care, and a partnership could help scale internationally and obtain regulatory approvals. The total addressable market is estimated at $9 billion annually in the US.
Cgix december investor-presentation
Cancer Genetics, Inc. is a personalized cancer diagnostics company that provides genomic testing services and proprietary diagnostic products. They have 5 commercially available diagnostic products that classify cancers like leukemia, lymphoma, kidney cancer, cervical cancer, and endometrial cancer. Their business model includes proprietary products, clinical cancer testing services, and clinical trial services. They aim to personalize cancer treatment by using biomarkers and genomic analysis to improve diagnosis, prognosis, and therapeutic selection compared to traditional methods.
Clinical Trials: Fact vs. Fiction, Courtney Hudson, CEO & Co-Founder, Emergin...
Clinical Trials: Fact vs. Fiction, Courtney Hudson, CEO & Co-Founder, Emergin...Ovarian Cancer Research Fund Alliance
Clinical trials provide a way to test new cancer therapies and determine their benefits and risks compared to existing standard treatments. This presentation discusses when patients should consider clinical trials, what types of trials are available for ovarian cancer, and key points about targeted therapies and genomic profiling. It notes that clinical trials now mirror the treatment paradigm for ovarian cancer, with trials available at each line of treatment. Over 40 phase 2 and 3 ovarian cancer trials and hundreds of phase 1 solid tumor trials are currently recruiting. Genomic profiling of a patient's tumor may help match them to targeted therapies in clinical trials based on specific molecular alterations.Similar to Ourotech slide deck (20)
Pros and Cons of Research Outcomes Week 12 discussion power point
Pros and Cons of Research Outcomes Week 12 discussion power point
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Clinical Trials: Fact vs. Fiction, Courtney Hudson, CEO & Co-Founder, Emergin...
Clinical Trials: Fact vs. Fiction, Courtney Hudson, CEO & Co-Founder, Emergin...
Recently uploaded
The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
Mercurius is named after the roman god mercurius, the god of trade and science. The planet mercurius is named after the same god. Mercurius is sometimes called hydrargyrum, means ‘watery silver’. Its shine and colour are very similar to silver, but mercury is a fluid at room temperatures. The name quick silver is a translation of hydrargyrum, where the word quick describes its tendency to scatter away in all directions.
The droplets have a tendency to conglomerate to one big mass, but on being shaken they fall apart into countless little droplets again. It is used to ignite explosives, like mercury fulminate, the explosive character is one of its general themes.
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
This document outlines policies and procedures for handling narcotic and controlled drugs in NABH accredited hospitals.
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
vonoprazan A novel drug for GERD presentation
Vonoprazan, a new potassium acid channel blocker used in the conditions of GERD and gastric ulcer, duodenal ulcer ....
Ketone bodies and metabolism-biochemistry
This slide consists of all the topics of ketone . This can be used for exam purpose for writing about Diabetic keto acidosis etc . Thank you
Recently uploaded (20)
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Ourotech slide deck
- 1. Ourotech Cancer treatment with certainty
- 2. Here’s how breast cancer is being fought today
- 3. 1st line treatment Herceptin combination 2nd line treatment T-DM1 3rd line treatment Xeloda 4th line treatment Hormone therapy Example: HER2+ Breast Cancer
- 4. Drug Resistance: Every cancer has a different weakness
- 5. The Problem Multiple drugs target the same cancer subtype but they don’t work on all patients Tumors can be resistant due to: - Genetic resistance/mutation - Tumor microenvironment - Interaction with other cancer cells - Interaction with healthy cells
- 6. Take the guess work out of cancer treatment
- 7. The Solution Obtain patient tumor sample from biopsy Grow tumors in 96 well plate using proprietary hydrogel Test the effectiveness of drugs and combination treatments Calculate necessary human dosage from test results Treat the patient
- 8. Obtain patient tumor sample from biopsy Grow tumors in 96 well plate using proprietary hydrogel Test the effectiveness of drugs and combination treatments Calculate necessary human dosage from test results Treat the patient
- 9. Proof of Concept: IC50 Drug Tested: Doxorubicin Human IC50: 702nM Ourotech IC50: 600~650nM Alginate IC50: 200nM IC50: industry standard measure of drug resistance Ourotech can predict this better than the competition
- 10. Core Technology Genesis Hydrogel that mimics conditions inside patients’ bodies for Stage 3 and 4 breast, colon, and brain cancers Allows doctors to culture patient tumors outside the body, create 3D tumor models and test drug resistance on patient derived tumors
- 11. $500/patient 1 hydrogel kit allows doctors to perform in vitro testing for 1 patient. Hydrogel is a consumable.
- 12. Market $7.05B $1.65B $204M 14.1M New Cancer Diagnoses/Year Worldwide 3.3M New Breast, Colorectal, Brain Cancer Diagnoses/Year Worldwide407K New Breast, Colorectal, Brain Cancer Diagnoses/Year in the US
- 13. Team Duleeka Ranatunga, CEO Prof Jonathan Blay Prof Shirley Tang William Lin, Head of R&D Christina Ryu, Business Development Ali Nikdel, R&DMichael Kim, Head of Finance
- 14. Funding Roadmap Strategic partnership with hospitals for preclinical trials Strategic partnership with big pharma client for clinical trials and distribution Start generating revenue by pharmaceutical drug testing services Optimize product based on drug testing and preclinical results Seed Series A
- 15. Funding and Milestones Ask: $1.5M Runway: 18 months Milestones Finish preclinical trials IRB and begin FDA 510K clearance process Generate revenues from pharma clients Develop new prototypes and IP
- 16. Traction 2 patents pending 2 academic pilots 2 pharma pilots, sales to start May 2017 1 Pre Clinical Trial In Progress Partnership for marketing
- 17. 2 Year Product Development Roadmap Develop more humanized hydrogels Integrate hydrogels with microfluidics and bioreactors Use big data for better drug dosage prediction Train machine learning algorithms to predict drug resistance Test immuno- therapies